Teva launches generic chemotherapy drug

IRVINE, Calif. — A division of Teva Pharmaceutical Industries has launched a generic chemotherapy drug, the company said.

Teva Health Systems announced the introduction of oxaliplatin injection in the 50-mg and 100-mg strengths.

The drug is a generic version of Sanofi's Eloxatin, which had sales of $1.7 billion during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.